SCHEMBL5844147

SCHEMBL5844147

CCOC(=O)Cc1c(Cl)nc(C)nc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 5/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 4/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
HPGD P15428 2/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27284948 0.91 MAPK1 (0.50) MAPK1KDM4ELMNAHSD17B10USP2
SCHEMBL1748473 0.89 MAPK1 (0.46) MAPK1KDM4ELMNAHSD17B10USP2
SCHEMBL1055154 0.87 MAPK1 (0.53) MAPK1KDM4ELMNAHSD17B10TSHR
SCHEMBL27289016 0.85 SMN1; SMN2 (0.46) MAPK1KDM4ELMNAHSD17B10USP2
SCHEMBL4772509 0.83 TSHR (0.40) MAPK1KDM4EHSD17B10USP2TSHR
SCHEMBL5844244 0.81 CRHR1 (0.40) MAPK1KDM4ELMNAHSD17B10USP2
SCHEMBL20040005 0.81 SMN1; SMN2 (0.41) MAPK1KDM4ELMNAHSD17B10HPGD
SCHEMBL12651960 0.81 MAPK1 (0.57) MAPK1KDM4EHSD17B10USP2TSHR
SCHEMBL9257344 0.80 KDM4E (0.42) MAPK1KDM4ELMNAHSD17B10USP2
SCHEMBL2062932 0.80 SMN1; SMN2 (0.44) MAPK1KDM4ELMNAHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7125880-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2006-10-24 US disclosed
US-7067664-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2006-06-27 US disclosed
US-6956047-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2005-10-18 US disclosed
US-20050032846-A1 Corticotropin releasing factor antagonists PFIZER INC. 2005-02-10 US disclosed
US-6844351-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2005-01-18 US disclosed
EP-0764166-B1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER (US) 2000-09-13 EP disclosed
US-5962479-A Corticotropin releasing factor antagonists PFIZER INC. (US) 1999-10-05 US disclosed
EP-0764166-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1997-03-26 EP disclosed
WO-1995033750-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1995-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032846-A1 Corticotropin releasing factor antagonists CRH, CRHR2, CRHR1 MAPK1 3258/4885KDM4E 4501/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.